These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 18821651)
1. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651 [TBL] [Abstract][Full Text] [Related]
2. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Borah BJ; Huang X; Zarotsky V; Globe D Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902 [TBL] [Abstract][Full Text] [Related]
3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
4. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
5. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424 [TBL] [Abstract][Full Text] [Related]
6. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150 [TBL] [Abstract][Full Text] [Related]
7. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306 [TBL] [Abstract][Full Text] [Related]
8. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. Davies A; Cifaldi MA; Segurado OG; Weisman MH J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363 [TBL] [Abstract][Full Text] [Related]
10. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Ollendorf DA; Peterson AN; Doyle J; Huse DM Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236 [TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis. Weycker D; Yu EB; Woolley JM; Oster G Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314 [TBL] [Abstract][Full Text] [Related]
12. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Harrold LR; Peterson D; Beard AJ; Gurwitz JH; Briesacher BA Am J Med; 2012 Sep; 125(9):937.e9-15. PubMed ID: 22682794 [TBL] [Abstract][Full Text] [Related]
13. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. Barra L; Pope JE; Payne M J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267 [TBL] [Abstract][Full Text] [Related]
14. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis. Santoleri F; Sorice P; Lasala R; Rizzo RC; Costantini A J Med Econ; 2014 May; 17(5):320-5. PubMed ID: 24641160 [TBL] [Abstract][Full Text] [Related]
15. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Harley CR; Frytak JR; Tandon N Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718 [TBL] [Abstract][Full Text] [Related]
16. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Tkacz J; Ellis L; Bolge SC; Meyer R; Brady BL; Ruetsch C Clin Ther; 2014 May; 36(5):737-47. PubMed ID: 24661783 [TBL] [Abstract][Full Text] [Related]
17. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Yazdani C; McLaughlin T; Cummins G; Doyle J Am J Manag Care; 2001 Sep; 7(13 Suppl):S419-26. PubMed ID: 11594238 [TBL] [Abstract][Full Text] [Related]
18. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. Gilbert TD; Smith D; Ollendorf DA BMC Musculoskelet Disord; 2004 Oct; 5(1):36. PubMed ID: 15485582 [TBL] [Abstract][Full Text] [Related]
19. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318 [TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Bonafede MM; Gandra SR; Fox KM; Wilson KL J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]